Literature DB >> 25996355

A Plan for Academic Biobank Solvency-Leveraging Resources and Applying Business Processes to Improve Sustainability.

Diane Uzarski1, James Burke2, Barbara Turner3, James Vroom3, Nancy Short3.   

Abstract

Researcher-initiated biobanks based at academic institutions contribute valuable biomarker and translational research advances to medicine. With many legacy banks once supported by federal funding, reductions in fiscal support threaten the future of existing and new biobanks. When the Brain Bank at Duke University's Bryan Alzheimer's Disease Center (ADRC) faced a funding crisis, a collaborative, multidisciplinary team embarked on a 2-year biobank sustainability project utilizing a comprehensive business strategy, dedicated project management, and a systems approach involving many Duke University entities. By synthesizing and applying existing knowledge, Duke Translational Medicine Institute created and launched a business model that can be adjusted and applied to legacy and start-up academic biobanks. This model provides a path to identify new funding mechanisms, while also emphasizing improved communication, business development, and a focus on collaborating with industry to improve access to biospecimens. Benchmarks for short-term Brain Bank stabilization have been successfully attained, and the evaluation of long-term sustainability metrics is ongoing.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  biobanking; biomarker research; sustainability

Mesh:

Substances:

Year:  2015        PMID: 25996355      PMCID: PMC4626329          DOI: 10.1111/cts.12287

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


  8 in total

1.  Biobanking in a fast moving world: an international perspective.

Authors:  Robert Hewitt; Pierre Hainaut
Journal:  J Natl Cancer Inst Monogr       Date:  2011

2.  Fee-for-service as a business model of growing importance: the academic biobank experience.

Authors:  Sandra A McDonald; Kara Sommerkamp; Maureen Egan-Palmer; Karen Kharasch; Victoria Holtschlag
Journal:  Biopreserv Biobank       Date:  2012-10       Impact factor: 2.300

3.  Biobank managers bemoan underuse of collected samples.

Authors:  Megan Scudellari
Journal:  Nat Med       Date:  2013-03       Impact factor: 53.440

4.  Biobankonomics: developing a sustainable business model approach for the formation of a human tissue biobank.

Authors:  Jimmie Vaught; Joyce Rogers; Todd Carolin; Carolyn Compton
Journal:  J Natl Cancer Inst Monogr       Date:  2011

5.  A framework for biobank sustainability.

Authors:  Peter H Watson; Sara Y Nussbeck; Candace Carter; Sheila O'Donoghue; Stefanie Cheah; Lise A M Matzke; Rebecca O Barnes; John Bartlett; Jane Carpenter; William E Grizzle; Randal N Johnston; Anne-Marie Mes-Masson; Leigh Murphy; Katherine Sexton; Lois Shepherd; Daniel Simeon-Dubach; Nikolajs Zeps; Brent Schacter
Journal:  Biopreserv Biobank       Date:  2014-02       Impact factor: 2.300

6.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

Authors:  E H Corder; A M Saunders; W J Strittmatter; D E Schmechel; P C Gaskell; G W Small; A D Roses; J L Haines; M A Pericak-Vance
Journal:  Science       Date:  1993-08-13       Impact factor: 47.728

Review 7.  Alzheimer's disease and the "Valley Of Death": not enough guidance from human brain tissue?

Authors:  Thomas G Beach
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

8.  Characterizing biobank organizations in the U.S.: results from a national survey.

Authors:  Gail E Henderson; R Jean Cadigan; Teresa P Edwards; Ian Conlon; Anders G Nelson; James P Evans; Arlene M Davis; Catherine Zimmer; Bryan J Weiner
Journal:  Genome Med       Date:  2013-01-25       Impact factor: 11.117

  8 in total
  3 in total

1.  Trends in Biobanking Business Planning: Initial Results of a Survey of Biobankers.

Authors:  Daniel Simeon-Dubach; Kirstin Goldring; Marianne K Henderson
Journal:  Biopreserv Biobank       Date:  2016-12-12       Impact factor: 2.300

Review 2.  Quality Assurance in Biobanking for Pre-Clinical Research.

Authors:  Daniel Simeon-Dubach; Steffen M Zeisberger; Simon P Hoerstrup
Journal:  Transfus Med Hemother       Date:  2016-09-17       Impact factor: 3.747

Review 3.  Brain tumor biobanking in the precision medicine era: building a high-quality resource for translational research in neuro-oncology.

Authors:  Quinn T Ostrom; Karen Devine; Jordonna Fulop; Yingli Wolinsky; Peter Liao; Lindsay Stetson; Marta Couce; Andrew E Sloan; Jill S Barnholtz-Sloan
Journal:  Neurooncol Pract       Date:  2016-12-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.